论文部分内容阅读
吲哚布芬(indobufen)是一种可逆性血小板环氧化酶抑制剂。本文采用随机、双盲、安慰剂对照试验评价了本品预防心源性血栓并发症的效果。 196例心脏病病人参加了本研究,均有发生心源性血栓的危险因素,其中90例病人为慢性房颤,106例为窦性心律。所有病人在过去的6个月内未服过抗凝药或抗血小板聚集剂,让病人随机接受本品100mg每日2次(98例)或安慰剂(98例),以后每3个月复查一次,共随访3年,主要研究终点为脑缺血发作(中风和一过性脑缺血发作),体循环栓塞、肺栓塞和致命性心肌梗塞。
Indobufen is a reversible inhibitor of platelet cyclooxygenase. This article uses a randomized, double-blind, placebo-controlled trial to evaluate the efficacy of this product to prevent cardiac complications of thrombosis. A total of 196 patients with heart disease participated in this study. All of them had risk factors of cardiogenic thrombosis, of which 90 were chronic atrial fibrillation and 106 were sinus rhythm. All patients in the past 6 months did not take anticoagulant or anti-platelet aggregation agent, so that patients randomized to receive 100mg twice daily (98 cases) or placebo (98 cases), after every 3 months review At a total of 3 years of follow-up, the primary end points were cerebral ischemic attack (stroke and transient ischemic attack), systemic embolism, pulmonary embolism, and fatal myocardial infarction.